New Delhi: The drug regulator’s subject expert committee on Thursday will be examining the applications that are looking for marketing authorization for Molnupiravir, the world’s very first medicine pill to treat symptomatic Covid19.
An urgent SEC meeting has been called out to review the presented proposals “under accelerated approval process”. Applications from around eight pharmaceutical companies based in India will be examined by the committee. Molnupiravir has shown better promising results in the treatment of mild to moderate Covid19 in adults, making the risk half of hospitalization and death. Various firms, including Dr Reddy’s, Natco, Cipla, Hetero, BDR Pharma and Sun Pharma are awaiting a green flag from the committee in India.
The development assumes importance as the generic antiviral oral pill, which is developed by Merck and Ridgeback has been proficient for people with high risk and weak immunity.